Pervasis Buyout Increases Shire’s Expertise In Regenerative Medicine
This article was originally published in The Pink Sheet Daily
Specialty pharma says it will position ESRD candidate Vascugel for success, just as Shire is doing with Dermagraft, acquired in last year’s buyout of Advanced BioHealing.
You may also be interested in...
A profound redefinition of the role of many cell types and biomaterials in regenerative medicine is under way as researchers have moved away from the notion that cells introduced into the body will integrate and become functioning tissue.
Jeff Jonas takes over Shire’s newly formed Regenerative Medicine business with plans for rapid growth, replacing Advanced BioHealing’s Kevin Rakin in the role.
The company hopes its newest division will mirror the growth of its rare disease unit, which was built largely through aggressive business development.